| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JULY 2014. Refer to TA318: Lubiprostone for treating chronic idiopathic constipation for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | lubiprostone (Amitiza®) | |
| Formulation | 24 micrograms capsule | |
| Reference number | 1910 | |
| Indication | Treatment of chronic idiopathic constipation and associated symptoms in adults |
|
| Company | Sucampo Pharma | |
| BNF chapter | Gastro-intestinal system | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 16/01/2013 | |
| Date of issue | 23/01/2013 | |
| NICE guidance | TA318: Lubiprostone for treating chronic idiopathic constipation |
|